HC Wainwright Has Negative Outlook for KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst E. White now expects that the company will earn ($4.37) per share for the quarter, down from their previous estimate of ($4.35). HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($4.19) EPS, Q3 2025 earnings at ($3.39) EPS, Q4 2025 earnings at ($3.81) EPS, FY2025 earnings at ($15.63) EPS, FY2026 earnings at ($11.15) EPS and FY2027 earnings at ($9.05) EPS.

Several other equities analysts have also recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $6.37 on Monday. Karyopharm Therapeutics has a 12 month low of $5.95 and a 12 month high of $25.50. The firm has a market capitalization of $53.64 million, a PE ratio of -6.25 and a beta of 0.06. The company’s 50 day simple moving average is $9.77 and its 200 day simple moving average is $11.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KPTI. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at about $27,000. Focus Partners Wealth acquired a new position in Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. purchased a new position in Karyopharm Therapeutics during the 4th quarter worth approximately $32,000. Two Sigma Advisers LP lifted its holdings in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).